サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1514999

遺伝性オロト酸尿症市場：医薬品タイプ別、適応症別、流通チャネル別、国別、地域別 - 産業分析、市場規模、市場シェア、2024年～2032年の予測

Hereditary Orotic Aciduria Market, By Drug Type, By Indication, By Distribution Channel, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
出版日: | 発行: AnalystView Market Insights | ページ情報: 英文 388 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=149.25円
遺伝性オロト酸尿症市場：医薬品タイプ別、適応症別、流通チャネル別、国別、地域別 - 産業分析、市場規模、市場シェア、2024年～2032年の予測
出版日: 2024年06月24日
発行: AnalystView Market Insights
ページ情報: 英文 388 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

レポートハイライト

遺伝性オロト酸尿症市場規模は2023年に3億5,789万米ドルとなり、2024年から2032年にかけてCAGR 4.6%で拡大

遺伝性オロト酸尿症市場-市場力学

市場需要を促進する政府の支援

政府の支援は、世界の遺伝性オロト酸尿症市場の拡大を推進する上で極めて重要です。数多くの国々が希少疾患を公衆衛生上の重要な課題として認識し、これらの領域の研究を強化するために様々な取り組みやプログラムを開始しています。例えば、2020年1月、国家衛生委員会は、希少疾患診断・治療全国ネットワークの組織と管理を強化するため、希少疾患診断・治療全国連携ネットワーク事務局を設立しました。この構想は、連携を促進し、連携ネットワークの全体的な役割を効果的に果たすことを目的としています。さらに、希少医薬品の開発は、世界の遺伝性オロト酸尿症市場の成長の主要な促進要因として浮上しています。希少疾病用医薬品は、希少疾病とも呼ばれ、人口のごく一部に罹患する希少な病状を対象とした医薬品です。

遺伝性オロト酸尿症市場-主要洞察

当社のリサーチアナリストの分析によると、世界市場は予測期間（2024-2032年）に約4.6%のCAGRで毎年成長すると推定されます。

薬剤タイプ別では、シチジン一リン酸（CMP）が2023年に最大市場シェアを示すと予測

適応症のセグメンテーションに基づくと、2023年には2型マーケティングが主要なタイプでした。

地域別では、北米が2023年に収益でリードしました。

遺伝性オロト酸尿症市場-セグメンテーション分析：

世界の遺伝性オロト酸尿症市場は、薬剤タイプ、適応症、流通チャネル、地域に基づいてセグメント化されます。

市場は薬剤タイプに基づいて2つのカテゴリーに分けられる：シチジン一リン酸とウリジン一リン酸です。遺伝性オロト酸尿症の治療において、シチジン一リン酸（CMP）は、細胞機能と遺伝子の完全性に不可欠なDNAとRNAの合成に不可欠な役割を果たすため、基礎治療薬として際立っています。この優位性は主に、DNA修復メカニズムやヌクレオチド代謝の欠損に関連する遺伝的障害を含む、タイプ1の適応症に対するCMPの有効性から生じています。これらの根本的な遺伝経路を標的とすることで、CMPに基づく治療法は、罹患者の症状を緩和し、疾患の進行を抑制することが期待されます。これらの複雑な遺伝的経路を調節するCMPの特異性は、この市場セグメントにおいて極めて重要な位置を占めており、遺伝性オロト酸尿症の管理におけるCMPの重要性を際立たせています。

市場は適応症によって2つのカテゴリーに分けられる：タイプ1とタイプ2です。2023年には、タイプ2の適応症が遺伝性オロト酸尿症市場の支配的勢力として台頭し、独自の課題と治療機会を提示します。これらの適応症は通常、ミトコンドリア機能障害やエネルギー代謝の障害を伴い、ウリジン一リン酸（UMP）に基づく治療が重要な役割を果たします。UMPに基づく治療は、ミトコンドリアの機能を強化し、細胞のエネルギー・バランスを回復させるのに役立つものであり、2型疾患の根本的な病態生理に対処する可能性を提供するものです。ミトコンドリアの機能障害を緩和するUMP療法の標的アプローチは、遺伝性オロト酸尿症の管理におけるUMP療法の重要性を強調し、UMP療法を2型適応症に対処するための重要なプレーヤーとして位置づけています。

遺伝性オロト酸尿症市場-地理的洞察

地域的には、この市場は北米、ラテンアメリカ、欧州、アジア太平洋、中東・アフリカで活動しています。顧客国は、これらの地域内の市場セグメントをさらに定義します。2023年には、北米が支配的なプレーヤーとして台頭し、この動向は当面続くと予想されます。この優位性は、高いヘルスケア支出や高度な医療インフラの存在など、いくつかの要因によって後押しされています。さらに、活発な研究開発活動が政府の支援政策と相まって、北米市場の牙城を揺るぎないものにしています。欧州も、新規治療法の開発を目指した研究開発活動の増加や、希少疾病への包括的な対処を目指した政府の支援策に牽引され、大きな市場シェアを占めています。

遺伝性オロト酸尿症市場-競合情勢：

遺伝性オロト酸尿症市場では、主要企業が独自の課題を克服し、その地位を維持するために様々な戦略を展開しています。主な戦略は、遺伝性オロト酸尿症（HOA）市場における希少疾患治療薬開発の課題を克服しながら、患者のアンメット・メディカル・ニーズに対応することに重点を置いています。有力なアプローチのひとつは、製薬企業、学術機関、患者支援団体が協力し、リソース、専門知識、患者の見識を共有することです。このような共同研究は、新規治療標的の同定、革新的治療アプローチの開発、効率的な臨床試験の設計を促進します。さらに、オーファンドラッグ指定やファストトラックステータスのような規制上のインセンティブは、HOA療法の開発・承認プロセスを迅速化することができます。市場参入戦略もまた重要な役割を果たし、償還を確保し、患者が手頃な価格で治療にアクセスできるようにする努力が含まれます。

目次

第1章 遺伝性オロト酸尿症市場概要

  • 調査範囲
  • 市場推定年

第2章 エグゼクティブサマリー

  • 市場内訳
  • 競合考察

第3章 遺伝性オロト酸尿症の主要市場動向

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 市場の将来動向

第4章 遺伝性オロト酸尿症産業研究

  • PEST分析
  • ポーターのファイブフォース分析
  • 成長見通しマッピング
  • 規制枠組み分析

第5章 遺伝性オロト酸尿症市場： COVID-19の影響分析

  • COVID-19以前の影響分析
  • COVID-19後の影響分析

第6章 遺伝性オロト酸尿症の市場情勢

  • 遺伝性オロト酸尿症の市場シェア分析、2023年
  • 主要メーカー別内訳データ
    • 既存企業の分析
    • 新興企業の分析

第7章 遺伝性オロト酸尿症市場：薬剤タイプ別

  • 概要
    • セグメントシェア分析
    • シチジン一リン酸
    • ウリジン一リン酸

第8章 遺伝性オロト酸尿症市場：適応症別

  • 概要
    • セグメントシェア分析
    • タイプ1
    • タイプ2

第9章 遺伝性オロト酸尿症市場：流通チャネル別

  • 概要
    • セグメントシェア分析
    • 病院薬局
    • 小売薬局
    • オンライン薬局

第10章 遺伝性オロト酸尿症市場：地域別

  • イントロダクション
  • 北米
    • 概要
    • 北米の主要メーカー
    • 米国
    • カナダ
  • 欧州
    • 概要
    • 欧州の主要メーカー
    • ドイツ
    • イタリア
    • 英国
    • フランス
    • ロシア
    • オランダ
    • スウェーデン
    • ポーランド
    • その他
  • アジア太平洋（APAC）
    • 概要
    • アジア太平洋地域の主要メーカー
    • インド
    • 中国
    • 日本
    • 韓国
    • オーストラリア
    • タイ
    • インドネシア
    • フィリピン
    • その他
  • ラテンアメリカ
    • 概要
    • ラテンアメリカの主要メーカー
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • その他
  • 中東およびアフリカ
    • 概要
    • 中東・アフリカの主要メーカー
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • トルコ
    • アルジェリア
    • エジプト
    • その他

第11章 主要ベンダー分析：遺伝性オロト酸尿症業界

  • 競争ダッシュボード
  • 企業プロファイル
    • Merck &Co. Inc.
    • SERB Pharmaceuticals
    • Others

第12章 アナリストの全方位展望

図表

List of Tables

  • TABLE List of data sources
  • TABLE Market drivers; Impact Analysis
  • TABLE Market restraints; Impact Analysis
  • TABLE Hereditary Orotic Aciduria Market: Drug Type Snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Drug Type
  • TABLE Global Hereditary Orotic Aciduria Market, by Drug Type 2019-2032 (USD Million)
  • TABLE Hereditary Orotic Aciduria Market: Indication Snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Indication
  • TABLE Global Hereditary Orotic Aciduria Market, by Indication 2019-2032 (USD Million)
  • TABLE Hereditary Orotic Aciduria Market: Distribution Channel Snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Distribution Channel
  • TABLE Global Hereditary Orotic Aciduria Market, by Distribution Channel 2019-2032 (USD Million)
  • TABLE Hereditary Orotic Aciduria Market: Regional snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Region
  • TABLE Global Hereditary Orotic Aciduria Market, by Region 2019-2032 (USD Million)
  • TABLE North America Hereditary Orotic Aciduria Market, by Country, 2019-2032 (USD Million)
  • TABLE North America Hereditary Orotic Aciduria Market, by Drug Type, 2019-2032 (USD Million)
  • TABLE North America Hereditary Orotic Aciduria Market, by Indication, 2019-2032 (USD Million)
  • TABLE North America Hereditary Orotic Aciduria Market, by Distribution Channel, 2019-2032 (USD Million)
  • TABLE Europe Hereditary Orotic Aciduria Market, by Country, 2019-2032 (USD Million)
  • TABLE Europe Hereditary Orotic Aciduria Market, by Drug Type, 2019-2032 (USD Million)
  • TABLE Europe Hereditary Orotic Aciduria Market, by Indication, 2019-2032 (USD Million)
  • TABLE Europe Hereditary Orotic Aciduria Market, by Distribution Channel, 2019-2032 (USD Million)
  • TABLE Asia Pacific Hereditary Orotic Aciduria Market, by Country, 2019-2032 (USD Million)
  • TABLE Asia Pacific Hereditary Orotic Aciduria Market, by Drug Type, 2019-2032 (USD Million)
  • TABLE Asia Pacific Hereditary Orotic Aciduria Market, by Indication, 2019-2032 (USD Million)
  • TABLE Asia Pacific Hereditary Orotic Aciduria Market, by Distribution Channel, 2019-2032 (USD Million)
  • TABLE Latin America Hereditary Orotic Aciduria Market, by Country, 2019-2032 (USD Million)
  • TABLE Latin America Hereditary Orotic Aciduria Market, by Drug Type, 2019-2032 (USD Million)
  • TABLE Latin America Hereditary Orotic Aciduria Market, by Indication, 2019-2032 (USD Million)
  • TABLE Latin America Hereditary Orotic Aciduria Market, by Distribution Channel, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Hereditary Orotic Aciduria Market, by Country, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Hereditary Orotic Aciduria Market, by Drug Type, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Hereditary Orotic Aciduria Market, by Indication, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Hereditary Orotic Aciduria Market, by Distribution Channel, 2019-2032 (USD Million)

List of Figures

  • FIGURE Hereditary Orotic Aciduria Market Segmentation
  • FIGURE Market research methodology
  • FIGURE Value chain analysis
  • FIGURE Porter's Five Forces Analysis
  • FIGURE Market Attractiveness Analysis
  • FIGURE COVID-19 Impact Analysis
  • FIGURE Pre & Post COVID-19 Impact Comparision Study
  • FIGURE Competitive Landscape; Key company market share analysis, 2023
  • FIGURE Drug Type segment market share analysis, 2023 & 2032
  • FIGURE Drug Type segment market size forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Indication segment market share analysis, 2023 & 2032
  • FIGURE Indication segment market size forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Distribution Channel segment market share analysis, 2023 & 2032
  • FIGURE Distribution Channel segment market size forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Regional segment market share analysis, 2023 & 2032
  • FIGURE Regional segment market size forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE North America Hereditary Orotic Aciduria Market share and leading players, 2023
  • FIGURE Europe Hereditary Orotic Aciduria Market share and leading players, 2023
  • FIGURE Asia Pacific Hereditary Orotic Aciduria Market share and leading players, 2023
  • FIGURE Latin America Hereditary Orotic Aciduria Market share and leading players, 2023
  • FIGURE Middle East and Africa Hereditary Orotic Aciduria Market share and leading players, 2023
  • FIGURE North America market share analysis by country, 2023
  • FIGURE U.S. Hereditary Orotic Aciduria Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Canada Hereditary Orotic Aciduria Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Europe Hereditary Orotic Aciduria Market share analysis by country, 2023
  • FIGURE Germany Hereditary Orotic Aciduria Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Spain Hereditary Orotic Aciduria Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Italy Hereditary Orotic Aciduria Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE France Hereditary Orotic Aciduria Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE UK Hereditary Orotic Aciduria Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Russia Hereditary Orotic Aciduria Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Netherlands Hereditary Orotic Aciduria Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Sweden Hereditary Orotic Aciduria Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Poland Hereditary Orotic Aciduria Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Rest of the Europe Hereditary Orotic Aciduria Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Asia Pacific Hereditary Orotic Aciduria Market share analysis by country, 2023
  • FIGURE India Hereditary Orotic Aciduria Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE China Hereditary Orotic Aciduria Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Japan Hereditary Orotic Aciduria Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE South Korea Hereditary Orotic Aciduria Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Australia Hereditary Orotic Aciduria Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Thailand Hereditary Orotic Aciduria Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Indonesia Hereditary Orotic Aciduria Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Philippines Hereditary Orotic Aciduria Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Rest of APAC Hereditary Orotic Aciduria Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Latin America Hereditary Orotic Aciduria Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Latin America Hereditary Orotic Aciduria Market share analysis by country, 2023
  • FIGURE Brazil Hereditary Orotic Aciduria Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Mexico Hereditary Orotic Aciduria Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Argentina Hereditary Orotic Aciduria Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Colombia Hereditary Orotic Aciduria Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Rest of LATAM Hereditary Orotic Aciduria Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Middle East and Africa Hereditary Orotic Aciduria Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Middle East and Africa Hereditary Orotic Aciduria Market share analysis by country, 2023
  • FIGURE Saudi Arabia Hereditary Orotic Aciduria Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE United Arab Emirates Hereditary Orotic Aciduria Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Israel Hereditary Orotic Aciduria Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Turkey Hereditary Orotic Aciduria Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Algeria Hereditary Orotic Aciduria Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Egypt Hereditary Orotic Aciduria Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Rest of MEA Hereditary Orotic Aciduria Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
目次
Product Code: ANV3108

REPORT HIGHLIGHT

Hereditary Orotic Aciduria Market size was valued at USD 357.89 Million in 2023, expanding at a CAGR of 4.6% from 2024 to 2032.

Hereditary Orotic Aciduria (HOA) is a rare genetic disorder characterized by deficiencies in enzymes crucial for the de novo pyrimidine synthesis pathway, resulting in the accumulation of orotic acid in the body. Despite its rarity, the HOA market has attracted attention from pharmaceutical companies and researchers due to the pressing unmet medical need for effective treatments. Strategies in this market often center around precision medicine approaches, such as gene therapy, enzyme replacement therapy, or small molecule interventions targeting specific metabolic pathways. Collaborations between biotech firms, academia, and pharmaceutical companies are pivotal in advancing research and development efforts, aiming not only to innovate therapies but also to raise awareness, improve diagnosis, and enhance patient care for those affected by this challenging condition. With the evolution of precision medicine, the HOA market holds promise for novel therapeutic interventions that may significantly enhance outcomes and improve the quality of life for patients.

Hereditary Orotic Aciduria Market- Market Dynamics

Government support to propel market demand

Government support is pivotal in propelling the expansion of the global hereditary orotic aciduria market. Numerous nations have acknowledged rare diseases as significant public health challenges and have initiated various initiatives and programs to bolster research in these domains. For instance, in January 2020, the National Health Commission established an office for the National Network for Collaboration in Rare Disease Diagnosis and Treatment to bolster the organization and management of the National Network for Rare Disease Diagnosis and Treatment. This initiative aims to facilitate collaboration and effectively fulfill the overall role of a collaborative network. Furthermore, the development of orphan drugs emerges as a major driver for the growth of the global hereditary orotic aciduria market. Orphan drugs are pharmaceutical agents intended for rare medical conditions, also termed as orphan diseases, which affect a small percentage of the population.

Hereditary Orotic Aciduria Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 4.6% over the forecast period (2024-2032)

Based on Drug Type segmentation, Cytidine monophosphate (CMP) was predicted to show maximum market share in the year 2023

Based on Indication segmentation, Type 2 marketing was the leading type in 2023

On the basis of region, North America was the leading revenue generator in 2023

Hereditary Orotic Aciduria Market- Segmentation Analysis:

The Global Hereditary Orotic Aciduria Market is segmented on the basis of Drug Type, Indication, Distribution Channel, and Region.

The market is divided into two categories based on Drug Type: Cytidine monophosphate and Uridine monophosphate. In the landscape of hereditary orotic aciduria treatments, Cytidine monophosphate (CMP) stands out as a cornerstone therapy due to its integral role in DNA and RNA synthesis, essential processes for cellular function and genetic integrity. This dominance primarily arises from CMP's efficacy in addressing Type 1 indications, which encompass genetic disorders associated with deficiencies in DNA repair mechanisms or nucleotide metabolism. By targeting these underlying genetic pathways, CMP-based therapies hold considerable promise in alleviating symptoms and impeding disease progression in affected individuals. The specificity of CMP in modulating these intricate genetic pathways underscores its pivotal position within this market segment, highlighting its significance in the management of hereditary orotic aciduria.

The market is divided into two categories based on Indication: Type 1 and Type 2. In 2023, Type 2 indications emerge as a dominant force within the hereditary orotic aciduria market, presenting unique challenges and therapeutic opportunities. These indications typically involve mitochondrial dysfunction or disruptions in energy metabolism, where therapies based on Uridine monophosphate (UMP) play a crucial role. UMP-based treatments are instrumental in bolstering mitochondrial function and restoring cellular energy balance, offering potential avenues for addressing the underlying pathophysiology of Type 2 conditions. The targeted approach of UMP therapies towards mitigating mitochondrial dysfunction underscores their significance in the management of hereditary orotic aciduria, positioning them as key players in addressing Type 2 indications.

Hereditary Orotic Aciduria Market- Geographical Insights

From a regional standpoint, this market operates in North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. Customer nations further define market segments within these regions. In 2023, North America emerges as a dominant player, a trend expected to persist in the foreseeable future. This dominance is fueled by several factors, including high healthcare expenditure and the presence of advanced healthcare infrastructure, which facilitate early detection and timely treatment interventions in the region. Additionally, robust research and development (R&D) activities, coupled with supportive government policies, further contribute to North America's stronghold in the market. Europe also commands a substantial market share, driven by increasing R&D efforts aimed at developing novel therapies and supportive government initiatives aimed at addressing rare diseases comprehensively.

Hereditary Orotic Aciduria Market- Competitive Landscape:

In the Hereditary Orotic Aciduria Market, major players deploy various strategies to navigate its unique challenges and maintain their positions. Key strategies focus on addressing the unmet medical needs of patients while navigating the challenges of rare disease drug development in the Hereditary Orotic Aciduria (HOA) market. One prominent approach involves fostering collaborations between pharmaceutical companies, academic institutions, and patient advocacy groups to pool resources, expertise, and patient insights. These collaborations facilitate the identification of novel therapeutic targets, the development of innovative treatment approaches, and the design of efficient clinical trials. Additionally, regulatory incentives such as orphan drug designation and fast-track status can expedite the development and approval process for HOA therapies. Market access strategies also play a crucial role, involving efforts to secure reimbursement and ensure affordable access to treatments for patients.

Recent Developments:

In January 2022, Pfizer Inc., a pharmaceutical company, and Beam, a pharmaceutical company, entered into an exclusive multi-target research collaboration to advance novel in vivo base editing programs for a range of rare diseases.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL HEREDITARY OROTIC ACIDURIA MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHT

Merck & Co. Inc.

SERB Pharmaceuticals

Others

GLOBAL HEREDITARY OROTIC ACIDURIA MARKET, BY DRUG TYPE - MARKET ANALYSIS, 2019 - 2032

  • Cytidine monophosphate
  • Uridine monophosphate

GLOBAL HEREDITARY OROTIC ACIDURIA MARKET, BY INDICATION- MARKET ANALYSIS, 2019 - 2032

  • Type 1
  • Type 2

GLOBAL HEREDITARY OROTIC ACIDURIA MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

GLOBAL HEREDITARY OROTIC ACIDURIA MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Hereditary Orotic Aciduria Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Hereditary Orotic Aciduria Market Snippet by Drug Type
    • 2.1.2. Hereditary Orotic Aciduria Market Snippet by Indication
    • 2.1.3. Hereditary Orotic Aciduria Market Snippet by Distribution Channel
    • 2.1.4. Hereditary Orotic Aciduria Market Snippet by Country
    • 2.1.5. Hereditary Orotic Aciduria Market Snippet by Region
  • 2.2. Competitive Insights

3. Hereditary Orotic Aciduria Key Market Trends

  • 3.1. Hereditary Orotic Aciduria Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Hereditary Orotic Aciduria Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Hereditary Orotic Aciduria Market Opportunities
  • 3.4. Hereditary Orotic Aciduria Market Future Trends

4. Hereditary Orotic Aciduria Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Hereditary Orotic Aciduria Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Hereditary Orotic Aciduria Market Landscape

  • 6.1. Hereditary Orotic Aciduria Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Hereditary Orotic Aciduria Market - By Drug Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Drug Type, 2023 & 2032 (%)
    • 7.1.2. Cytidine monophosphate
    • 7.1.3. Uridine monophosphate

8. Hereditary Orotic Aciduria Market - By Indication

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Indication, 2023 & 2032 (%)
    • 8.1.2. Type 1
    • 8.1.3. Type 2

9. Hereditary Orotic Aciduria Market - By Distribution Channel

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Distribution Channel, 2023 & 2032 (%)
    • 9.1.2. Hospital Pharmacies
    • 9.1.3. Retail Pharmacies
    • 9.1.4. Online Pharmacies

10. Hereditary Orotic Aciduria Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Hereditary Orotic Aciduria Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Hereditary Orotic Aciduria Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Hereditary Orotic Aciduria Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Hereditary Orotic Aciduria Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Hereditary Orotic Aciduria Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Hereditary Orotic Aciduria Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. Merck & Co. Inc.
    • 11.2.2. SERB Pharmaceuticals
    • 11.2.3. Others

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us